 Paul Norman
Concepts (733)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, KIR | 59 | 2025 | 98 | 10.440 |
Why?
| | Killer Cells, Natural | 55 | 2025 | 449 | 7.120 |
Why?
| | Haplotypes | 44 | 2025 | 494 | 4.400 |
Why?
| | Alleles | 48 | 2025 | 891 | 3.810 |
Why?
| | Genes, MHC Class I | 12 | 2022 | 35 | 3.580 |
Why?
| | Histocompatibility Antigens Class I | 17 | 2024 | 203 | 3.490 |
Why?
| | HLA Antigens | 21 | 2024 | 240 | 3.160 |
Why?
| | HLA-B Antigens | 21 | 2025 | 62 | 3.070 |
Why?
| | HLA-C Antigens | 19 | 2024 | 35 | 3.050 |
Why?
| | Polymorphism, Genetic | 32 | 2024 | 660 | 2.580 |
Why?
| | Receptors, KIR3DL1 | 13 | 2024 | 18 | 2.290 |
Why?
| | Genotype | 36 | 2025 | 1916 | 2.150 |
Why?
| | Immunogenetics | 5 | 2024 | 7 | 2.110 |
Why?
| | Receptors, KIR2DL1 | 12 | 2024 | 19 | 2.090 |
Why?
| | Evolution, Molecular | 18 | 2022 | 493 | 1.770 |
Why?
| | Genetic Variation | 19 | 2025 | 991 | 1.370 |
Why?
| | High-Throughput Nucleotide Sequencing | 15 | 2025 | 539 | 1.360 |
Why?
| | Selection, Genetic | 12 | 2024 | 273 | 1.320 |
Why?
| | HLA-A Antigens | 11 | 2023 | 55 | 1.310 |
Why?
| | Receptors, KIR3DS1 | 4 | 2022 | 6 | 1.260 |
Why?
| | Employment | 4 | 2025 | 178 | 1.240 |
Why?
| | Humans | 201 | 2025 | 137585 | 1.220 |
Why?
| | Receptors, Immunologic | 10 | 2021 | 216 | 1.150 |
Why?
| | Socioeconomic Factors | 8 | 2024 | 1289 | 1.120 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2025 | 89 | 1.100 |
Why?
| | Health Status Disparities | 6 | 2024 | 289 | 1.090 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 52 | 1.040 |
Why?
| | Retirement | 2 | 2025 | 31 | 1.010 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 74 | 1.000 |
Why?
| | Gene Frequency | 19 | 2025 | 521 | 0.980 |
Why?
| | Qualitative Research | 8 | 2025 | 1386 | 0.960 |
Why?
| | England | 12 | 2025 | 97 | 0.930 |
Why?
| | United Kingdom | 13 | 2025 | 318 | 0.910 |
Why?
| | Sequence Deletion | 1 | 2025 | 183 | 0.890 |
Why?
| | Immunogenetic Phenomena | 2 | 2022 | 7 | 0.870 |
Why?
| | Medication Errors | 1 | 2024 | 95 | 0.860 |
Why?
| | Genome, Human | 6 | 2025 | 425 | 0.860 |
Why?
| | Residence Characteristics | 3 | 2021 | 351 | 0.850 |
Why?
| | Pre-Eclampsia | 3 | 2020 | 190 | 0.810 |
Why?
| | Focus Groups | 3 | 2024 | 522 | 0.800 |
Why?
| | Multimorbidity | 1 | 2023 | 47 | 0.800 |
Why?
| | Ligands | 15 | 2023 | 664 | 0.790 |
Why?
| | Complement C4 | 2 | 2025 | 28 | 0.770 |
Why?
| | Herpesviridae | 1 | 2022 | 23 | 0.770 |
Why?
| | Receptors, Natural Killer Cell | 6 | 2022 | 16 | 0.770 |
Why?
| | Genome-Wide Association Study | 4 | 2024 | 1431 | 0.750 |
Why?
| | Minority Groups | 5 | 2024 | 266 | 0.740 |
Why?
| | Binge Drinking | 2 | 2021 | 43 | 0.740 |
Why?
| | Quality of Life | 15 | 2025 | 2892 | 0.740 |
Why?
| | Adaptation, Psychological | 7 | 2024 | 655 | 0.730 |
Why?
| | Primates | 3 | 2019 | 126 | 0.730 |
Why?
| | Health Promotion | 6 | 2024 | 741 | 0.730 |
Why?
| | Herpesviridae Infections | 1 | 2023 | 147 | 0.720 |
Why?
| | Patient Safety | 1 | 2024 | 314 | 0.710 |
Why?
| | Communicable Diseases | 1 | 2023 | 159 | 0.700 |
Why?
| | Seizures | 4 | 2019 | 426 | 0.690 |
Why?
| | DNA Copy Number Variations | 6 | 2025 | 182 | 0.690 |
Why?
| | Hearing Aids | 1 | 2021 | 77 | 0.680 |
Why?
| | Genetic Predisposition to Disease | 14 | 2025 | 2426 | 0.680 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 900 | 0.670 |
Why?
| | Major Histocompatibility Complex | 4 | 2025 | 227 | 0.660 |
Why?
| | Mortality | 2 | 2014 | 362 | 0.660 |
Why?
| | Censuses | 3 | 2017 | 31 | 0.650 |
Why?
| | Cross-Sectional Studies | 15 | 2024 | 5472 | 0.650 |
Why?
| | Aortic Aneurysm, Abdominal | 3 | 2017 | 140 | 0.640 |
Why?
| | Genetics, Population | 10 | 2021 | 214 | 0.640 |
Why?
| | Somatoform Disorders | 2 | 2016 | 38 | 0.620 |
Why?
| | Intensive Care Units | 1 | 2024 | 827 | 0.610 |
Why?
| | Hematopoietic Stem Cell Transplantation | 6 | 2024 | 622 | 0.600 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2023 | 367 | 0.600 |
Why?
| | Male | 68 | 2025 | 67762 | 0.600 |
Why?
| | Peptides | 4 | 2022 | 985 | 0.600 |
Why?
| | Poverty Areas | 2 | 2019 | 39 | 0.590 |
Why?
| | Point Mutation | 3 | 2017 | 235 | 0.580 |
Why?
| | Hearing Loss | 1 | 2021 | 221 | 0.580 |
Why?
| | Female | 75 | 2025 | 73304 | 0.580 |
Why?
| | Adult | 51 | 2025 | 37929 | 0.580 |
Why?
| | Receptors, KIR2DL4 | 3 | 2016 | 4 | 0.570 |
Why?
| | Heterozygote | 1 | 2019 | 293 | 0.570 |
Why?
| | Pan troglodytes | 9 | 2017 | 63 | 0.560 |
Why?
| | Blood Vessel Prosthesis Implantation | 2 | 2022 | 202 | 0.560 |
Why?
| | Language | 1 | 2020 | 292 | 0.560 |
Why?
| | Psoriasis | 3 | 2024 | 102 | 0.550 |
Why?
| | Health Status | 3 | 2025 | 792 | 0.540 |
Why?
| | Genotyping Techniques | 4 | 2025 | 75 | 0.540 |
Why?
| | Leukemia | 1 | 2019 | 240 | 0.530 |
Why?
| | Rural Health Services | 3 | 2025 | 128 | 0.520 |
Why?
| | Protein Binding | 10 | 2019 | 2224 | 0.520 |
Why?
| | Mucins | 1 | 2017 | 73 | 0.520 |
Why?
| | Linkage Disequilibrium | 10 | 2017 | 268 | 0.510 |
Why?
| | Middle Aged | 44 | 2025 | 33479 | 0.500 |
Why?
| | Endovascular Procedures | 2 | 2022 | 312 | 0.490 |
Why?
| | Blood Vessel Prosthesis | 2 | 2022 | 127 | 0.490 |
Why?
| | Burns | 3 | 2024 | 325 | 0.490 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2015 | 41 | 0.480 |
Why?
| | Population Dynamics | 2 | 2018 | 151 | 0.480 |
Why?
| | Weight Loss | 3 | 2019 | 787 | 0.480 |
Why?
| | Immunoglobulins | 4 | 2023 | 171 | 0.470 |
Why?
| | Family Relations | 1 | 2015 | 91 | 0.470 |
Why?
| | Exons | 1 | 2016 | 355 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 12 | 2025 | 2189 | 0.450 |
Why?
| | Population | 1 | 2014 | 35 | 0.450 |
Why?
| | Self Concept | 3 | 2024 | 253 | 0.430 |
Why?
| | Wales | 5 | 2025 | 23 | 0.420 |
Why?
| | Receptors, KIR2DL2 | 5 | 2021 | 6 | 0.420 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 413 | 0.420 |
Why?
| | Immunity, Innate | 7 | 2024 | 828 | 0.420 |
Why?
| | Receptors, KIR2DL3 | 6 | 2017 | 9 | 0.420 |
Why?
| | Terminally Ill | 1 | 2014 | 37 | 0.420 |
Why?
| | Sequence Analysis, DNA | 8 | 2025 | 812 | 0.420 |
Why?
| | Behavior Therapy | 4 | 2023 | 264 | 0.420 |
Why?
| | Malaria | 1 | 2013 | 63 | 0.400 |
Why?
| | Emergency Service, Hospital | 7 | 2025 | 2069 | 0.400 |
Why?
| | Cell Line | 8 | 2019 | 2847 | 0.400 |
Why?
| | Overweight | 1 | 2017 | 558 | 0.400 |
Why?
| | Longitudinal Studies | 9 | 2025 | 2844 | 0.400 |
Why?
| | Histocompatibility Testing | 4 | 2024 | 126 | 0.400 |
Why?
| | Stents | 2 | 2022 | 527 | 0.390 |
Why?
| | Young Adult | 20 | 2024 | 13209 | 0.390 |
Why?
| | Empathy | 2 | 2024 | 173 | 0.380 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1353 | 0.370 |
Why?
| | Depression | 3 | 2023 | 1397 | 0.360 |
Why?
| | Aged | 26 | 2025 | 23961 | 0.360 |
Why?
| | Intention | 3 | 2021 | 170 | 0.360 |
Why?
| | Infant Mortality | 2 | 2024 | 116 | 0.360 |
Why?
| | Cytomegalovirus | 3 | 2024 | 157 | 0.360 |
Why?
| | Molecular Sequence Data | 14 | 2014 | 2900 | 0.350 |
Why?
| | Emergency Medicine | 2 | 2024 | 226 | 0.350 |
Why?
| | Life Style | 4 | 2017 | 490 | 0.350 |
Why?
| | T-Lymphocytes | 6 | 2024 | 1996 | 0.350 |
Why?
| | Universities | 3 | 2021 | 433 | 0.340 |
Why?
| | Behcet Syndrome | 2 | 2021 | 18 | 0.330 |
Why?
| | Alcoholism | 1 | 2017 | 807 | 0.330 |
Why?
| | Health Behavior | 6 | 2025 | 762 | 0.330 |
Why?
| | Biological Evolution | 5 | 2019 | 474 | 0.330 |
Why?
| | Patient Compliance | 3 | 2025 | 581 | 0.320 |
Why?
| | Epitopes | 8 | 2019 | 479 | 0.320 |
Why?
| | Motor Neuron Disease | 2 | 2019 | 20 | 0.320 |
Why?
| | Amino Acid Sequence | 9 | 2019 | 2139 | 0.310 |
Why?
| | Body Image | 3 | 2024 | 95 | 0.310 |
Why?
| | Australia | 4 | 2024 | 315 | 0.310 |
Why?
| | Malnutrition | 2 | 2021 | 83 | 0.310 |
Why?
| | Cytomegalovirus Infections | 2 | 2024 | 192 | 0.300 |
Why?
| | Recombination, Genetic | 2 | 2010 | 204 | 0.300 |
Why?
| | Models, Molecular | 5 | 2019 | 1570 | 0.300 |
Why?
| | Meiosis | 1 | 2009 | 82 | 0.300 |
Why?
| | Antigens, CD | 5 | 2017 | 521 | 0.300 |
Why?
| | Rural Population | 2 | 2018 | 563 | 0.300 |
Why?
| | Urban Population | 1 | 2011 | 479 | 0.290 |
Why?
| | Adolescent | 19 | 2024 | 21513 | 0.290 |
Why?
| | Phylogeny | 12 | 2017 | 904 | 0.290 |
Why?
| | Life Change Events | 2 | 2019 | 151 | 0.280 |
Why?
| | Alcohol Drinking | 4 | 2021 | 828 | 0.280 |
Why?
| | Students | 3 | 2021 | 622 | 0.280 |
Why?
| | Energy Intake | 3 | 2025 | 485 | 0.280 |
Why?
| | Chronic Disease | 1 | 2014 | 1793 | 0.280 |
Why?
| | China | 3 | 2024 | 217 | 0.280 |
Why?
| | Genomics | 6 | 2025 | 795 | 0.270 |
Why?
| | Object Attachment | 2 | 2019 | 44 | 0.270 |
Why?
| | Oceania | 2 | 2024 | 4 | 0.270 |
Why?
| | Income | 2 | 2019 | 202 | 0.270 |
Why?
| | Homozygote | 2 | 2025 | 203 | 0.270 |
Why?
| | Signal Transduction | 4 | 2019 | 5079 | 0.270 |
Why?
| | Multigene Family | 3 | 2018 | 198 | 0.260 |
Why?
| | Immune System | 2 | 2019 | 177 | 0.260 |
Why?
| | Self-Management | 2 | 2019 | 176 | 0.260 |
Why?
| | Egypt | 2 | 2023 | 11 | 0.260 |
Why?
| | Infant, Newborn | 7 | 2024 | 6079 | 0.260 |
Why?
| | Caregivers | 4 | 2025 | 877 | 0.250 |
Why?
| | Centromere | 3 | 2025 | 59 | 0.250 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 6 | 0.250 |
Why?
| | Infant | 8 | 2024 | 9465 | 0.250 |
Why?
| | Animals | 29 | 2025 | 36940 | 0.250 |
Why?
| | Phenotype | 8 | 2024 | 3196 | 0.250 |
Why?
| | Virus Activation | 2 | 2024 | 88 | 0.250 |
Why?
| | Codon | 2 | 2016 | 89 | 0.250 |
Why?
| | Amino Acid Substitution | 5 | 2016 | 307 | 0.250 |
Why?
| | Quality Improvement | 2 | 2024 | 1178 | 0.250 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2025 | 17 | 0.240 |
Why?
| | Software | 4 | 2025 | 665 | 0.240 |
Why?
| | Thymus Gland | 2 | 2024 | 312 | 0.240 |
Why?
| | Child | 11 | 2024 | 21935 | 0.240 |
Why?
| | Rural Health | 1 | 2025 | 80 | 0.230 |
Why?
| | Hominidae | 2 | 2019 | 85 | 0.230 |
Why?
| | Industry | 1 | 2025 | 68 | 0.230 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2025 | 37 | 0.230 |
Why?
| | Occupations | 1 | 2024 | 49 | 0.230 |
Why?
| | Capacity Building | 1 | 2025 | 63 | 0.230 |
Why?
| | Interpersonal Relations | 2 | 2019 | 397 | 0.220 |
Why?
| | Smoking | 5 | 2019 | 1627 | 0.220 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2024 | 17 | 0.220 |
Why?
| | Attitude to Health | 3 | 2019 | 439 | 0.220 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1046 | 0.220 |
Why?
| | Obesity | 1 | 2017 | 2992 | 0.220 |
Why?
| | Th17 Cells | 1 | 2025 | 108 | 0.220 |
Why?
| | Iodine Radioisotopes | 1 | 2024 | 145 | 0.220 |
Why?
| | Nutrition Therapy | 2 | 2025 | 37 | 0.210 |
Why?
| | Phenylurea Compounds | 1 | 2024 | 97 | 0.210 |
Why?
| | Parkinson Disease | 2 | 2020 | 493 | 0.210 |
Why?
| | Arabs | 2 | 2020 | 8 | 0.210 |
Why?
| | Pedigree | 1 | 2025 | 514 | 0.210 |
Why?
| | Quinolines | 2 | 2024 | 178 | 0.210 |
Why?
| | Cohort Studies | 8 | 2021 | 5742 | 0.210 |
Why?
| | Registries | 4 | 2021 | 2035 | 0.210 |
Why?
| | Alopecia Areata | 1 | 2023 | 13 | 0.210 |
Why?
| | HLA-DP beta-Chains | 1 | 2023 | 86 | 0.200 |
Why?
| | Immunity, Cellular | 1 | 2005 | 268 | 0.200 |
Why?
| | Gene Dosage | 3 | 2021 | 140 | 0.200 |
Why?
| | Waiting Lists | 1 | 2025 | 266 | 0.200 |
Why?
| | Efficiency, Organizational | 2 | 2025 | 140 | 0.200 |
Why?
| | Iran | 2 | 2020 | 43 | 0.200 |
Why?
| | Incidence | 5 | 2020 | 2804 | 0.200 |
Why?
| | Computational Biology | 2 | 2025 | 644 | 0.200 |
Why?
| | Unemployment | 1 | 2022 | 43 | 0.200 |
Why?
| | Social Stigma | 1 | 2024 | 137 | 0.200 |
Why?
| | Colon | 1 | 2025 | 282 | 0.200 |
Why?
| | Transplantation Conditioning | 1 | 2024 | 170 | 0.200 |
Why?
| | Cardiovascular Diseases | 3 | 2021 | 2111 | 0.200 |
Why?
| | Leukocytes | 1 | 2004 | 311 | 0.200 |
Why?
| | Sequence Alignment | 3 | 2021 | 343 | 0.190 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 5778 | 0.190 |
Why?
| | Health Services Research | 1 | 2025 | 404 | 0.190 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 1142 | 0.190 |
Why?
| | Africa, Southern | 2 | 2021 | 8 | 0.190 |
Why?
| | Telomere | 4 | 2025 | 280 | 0.190 |
Why?
| | Patient Transfer | 1 | 2024 | 176 | 0.190 |
Why?
| | Colitis | 1 | 2025 | 266 | 0.190 |
Why?
| | Toll-Like Receptor 3 | 1 | 2021 | 28 | 0.190 |
Why?
| | Health | 1 | 2022 | 84 | 0.180 |
Why?
| | Longevity | 1 | 2023 | 165 | 0.180 |
Why?
| | Artificial Intelligence | 1 | 2025 | 279 | 0.180 |
Why?
| | Multilevel Analysis | 1 | 2021 | 31 | 0.180 |
Why?
| | Age Factors | 5 | 2018 | 3295 | 0.180 |
Why?
| | Eczema | 1 | 2022 | 69 | 0.180 |
Why?
| | New Zealand | 3 | 2018 | 56 | 0.180 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 336 | 0.180 |
Why?
| | Genomic Structural Variation | 1 | 2021 | 12 | 0.180 |
Why?
| | Mindfulness | 1 | 2023 | 117 | 0.180 |
Why?
| | Yersinia pestis | 1 | 2021 | 45 | 0.180 |
Why?
| | Nutritionists | 1 | 2021 | 19 | 0.180 |
Why?
| | Malaysia | 1 | 2020 | 5 | 0.180 |
Why?
| | Professional Practice Location | 1 | 2021 | 29 | 0.180 |
Why?
| | HLA-DRB1 Chains | 3 | 2019 | 112 | 0.180 |
Why?
| | Protein Interaction Domains and Motifs | 2 | 2019 | 150 | 0.170 |
Why?
| | HLA-D Antigens | 1 | 2021 | 34 | 0.170 |
Why?
| | Nutritional Support | 1 | 2021 | 34 | 0.170 |
Why?
| | Plague | 1 | 2021 | 60 | 0.170 |
Why?
| | Physical Appearance, Body | 3 | 2024 | 3 | 0.170 |
Why?
| | Peripheral Arterial Disease | 2 | 2018 | 475 | 0.170 |
Why?
| | Motivation | 1 | 2025 | 570 | 0.170 |
Why?
| | Exercise | 5 | 2019 | 2057 | 0.170 |
Why?
| | Clinical Protocols | 2 | 2019 | 271 | 0.170 |
Why?
| | Thyroid Neoplasms | 1 | 2024 | 343 | 0.170 |
Why?
| | Hearing Tests | 1 | 2020 | 47 | 0.170 |
Why?
| | Child, Preschool | 7 | 2022 | 11074 | 0.160 |
Why?
| | Pregnancy | 6 | 2020 | 6763 | 0.160 |
Why?
| | Mentoring | 1 | 2023 | 149 | 0.160 |
Why?
| | Intestinal Mucosa | 1 | 2025 | 623 | 0.160 |
Why?
| | Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 2 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 806 | 0.160 |
Why?
| | Transportation | 1 | 2019 | 53 | 0.160 |
Why?
| | Clathrin Heavy Chains | 1 | 2019 | 3 | 0.160 |
Why?
| | Protozoan Infections | 1 | 2019 | 11 | 0.160 |
Why?
| | HLA-DP Antigens | 1 | 2019 | 33 | 0.160 |
Why?
| | Diet, Diabetic | 1 | 2019 | 34 | 0.160 |
Why?
| | Hearing | 1 | 2020 | 118 | 0.160 |
Why?
| | Health Personnel | 3 | 2021 | 710 | 0.160 |
Why?
| | Multiple Sclerosis | 1 | 2025 | 455 | 0.160 |
Why?
| | B-Lymphocytes | 4 | 2017 | 847 | 0.150 |
Why?
| | Diabetic Foot | 1 | 2019 | 24 | 0.150 |
Why?
| | Base Sequence | 3 | 2016 | 2181 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 804 | 0.150 |
Why?
| | Bicycling | 1 | 2019 | 114 | 0.150 |
Why?
| | Noninvasive Ventilation | 1 | 2019 | 51 | 0.150 |
Why?
| | Phylogeography | 1 | 2019 | 54 | 0.150 |
Why?
| | Parents | 2 | 2024 | 1347 | 0.150 |
Why?
| | Receptors, Cell Surface | 1 | 2001 | 385 | 0.150 |
Why?
| | Sex Factors | 4 | 2019 | 2071 | 0.150 |
Why?
| | Diet | 4 | 2019 | 1278 | 0.150 |
Why?
| | Canada | 3 | 2024 | 418 | 0.150 |
Why?
| | Indians, North American | 2 | 2015 | 643 | 0.150 |
Why?
| | Africa South of the Sahara | 2 | 2019 | 48 | 0.140 |
Why?
| | Indians, South American | 2 | 2009 | 25 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2024 | 718 | 0.140 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 54 | 0.140 |
Why?
| | Cluster Analysis | 2 | 2017 | 499 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 630 | 0.140 |
Why?
| | Aggression | 1 | 2020 | 202 | 0.140 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 10 | 0.140 |
Why?
| | Eye Diseases | 1 | 2019 | 87 | 0.140 |
Why?
| | Syk Kinase | 1 | 2017 | 21 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2024 | 442 | 0.140 |
Why?
| | Middle East | 1 | 2017 | 15 | 0.140 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 174 | 0.140 |
Why?
| | Flow Cytometry | 7 | 2018 | 1178 | 0.140 |
Why?
| | Names | 1 | 2017 | 15 | 0.140 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 570 | 0.140 |
Why?
| | Binding Sites | 6 | 2015 | 1303 | 0.140 |
Why?
| | Walking | 2 | 2019 | 529 | 0.140 |
Why?
| | Epilepsy | 2 | 2019 | 333 | 0.140 |
Why?
| | Genetic Testing | 4 | 2002 | 460 | 0.140 |
Why?
| | Pan paniscus | 1 | 2017 | 4 | 0.140 |
Why?
| | Lymphocyte Subsets | 3 | 2009 | 87 | 0.140 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 27 | 0.140 |
Why?
| | Contig Mapping | 1 | 2017 | 11 | 0.140 |
Why?
| | Immunodominant Epitopes | 1 | 2017 | 27 | 0.140 |
Why?
| | Pongo | 1 | 2017 | 6 | 0.140 |
Why?
| | Osteosarcoma | 1 | 2018 | 74 | 0.140 |
Why?
| | Air Pollution | 1 | 2021 | 316 | 0.130 |
Why?
| | Aorta, Abdominal | 1 | 2017 | 46 | 0.130 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 861 | 0.130 |
Why?
| | Transplantation, Homologous | 4 | 2024 | 416 | 0.130 |
Why?
| | Prevalence | 4 | 2019 | 2734 | 0.130 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2607 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 273 | 0.130 |
Why?
| | Alcoholic Beverages | 1 | 2017 | 28 | 0.130 |
Why?
| | Risk Factors | 11 | 2025 | 10388 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 101 | 0.130 |
Why?
| | Models, Genetic | 4 | 2015 | 600 | 0.130 |
Why?
| | Antimicrobial Stewardship | 1 | 2019 | 118 | 0.130 |
Why?
| | Angiotensin II | 1 | 2017 | 99 | 0.130 |
Why?
| | Anxiety | 3 | 2023 | 1035 | 0.130 |
Why?
| | Virus Diseases | 1 | 2019 | 212 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 402 | 0.130 |
Why?
| | Reference Standards | 1 | 2017 | 186 | 0.130 |
Why?
| | Allied Health Personnel | 1 | 2016 | 46 | 0.130 |
Why?
| | Gene Flow | 2 | 2015 | 86 | 0.130 |
Why?
| | Sarcoma, Ewing | 1 | 2018 | 97 | 0.130 |
Why?
| | Open Reading Frames | 1 | 2017 | 123 | 0.130 |
Why?
| | Polymerase Chain Reaction | 5 | 2017 | 1062 | 0.130 |
Why?
| | Feeding Behavior | 2 | 2019 | 654 | 0.130 |
Why?
| | Women's Health | 1 | 2019 | 372 | 0.130 |
Why?
| | Molecular Typing | 1 | 2016 | 22 | 0.130 |
Why?
| | Placentation | 2 | 2016 | 45 | 0.130 |
Why?
| | Environmental Exposure | 1 | 2021 | 579 | 0.130 |
Why?
| | HIV-1 | 1 | 2022 | 864 | 0.130 |
Why?
| | Herpesvirus 4, Human | 1 | 2017 | 166 | 0.130 |
Why?
| | Self Care | 2 | 2016 | 380 | 0.120 |
Why?
| | Dissociative Disorders | 1 | 2015 | 22 | 0.120 |
Why?
| | Crohn Disease | 1 | 2019 | 243 | 0.120 |
Why?
| | Curriculum | 1 | 2022 | 992 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 934 | 0.120 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7635 | 0.120 |
Why?
| | Sf9 Cells | 1 | 2015 | 9 | 0.120 |
Why?
| | Donor Selection | 1 | 2016 | 77 | 0.120 |
Why?
| | Gene Expression | 4 | 2018 | 1502 | 0.120 |
Why?
| | Spodoptera | 1 | 2015 | 40 | 0.120 |
Why?
| | Chest Pain | 1 | 2016 | 91 | 0.120 |
Why?
| | Case-Control Studies | 6 | 2024 | 3556 | 0.120 |
Why?
| | Baculoviridae | 1 | 2015 | 44 | 0.120 |
Why?
| | Human Migration | 1 | 2015 | 22 | 0.120 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2015 | 38 | 0.120 |
Why?
| | Bone Neoplasms | 1 | 2018 | 247 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1692 | 0.120 |
Why?
| | Insecta | 1 | 2015 | 67 | 0.120 |
Why?
| | Research Report | 1 | 2015 | 83 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
| | Social Class | 1 | 2017 | 282 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.110 |
Why?
| | Amino Acid Motifs | 5 | 2019 | 225 | 0.110 |
Why?
| | Polynesia | 1 | 2014 | 4 | 0.110 |
Why?
| | Adolescent Behavior | 1 | 2020 | 530 | 0.110 |
Why?
| | Biological Assay | 1 | 2015 | 124 | 0.110 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2015 | 88 | 0.110 |
Why?
| | Receptors, KIR3DL2 | 2 | 2015 | 2 | 0.110 |
Why?
| | Time Factors | 8 | 2025 | 6828 | 0.110 |
Why?
| | Isoantibodies | 1 | 1995 | 60 | 0.110 |
Why?
| | Muscle Weakness | 1 | 2014 | 88 | 0.110 |
Why?
| | DNA | 3 | 2021 | 1459 | 0.110 |
Why?
| | Glucose | 1 | 2019 | 1020 | 0.110 |
Why?
| | Attitude of Health Personnel | 2 | 2019 | 1171 | 0.110 |
Why?
| | Risk Reduction Behavior | 1 | 2015 | 220 | 0.110 |
Why?
| | Protein Folding | 1 | 2015 | 280 | 0.110 |
Why?
| | Mammals | 1 | 2015 | 283 | 0.110 |
Why?
| | Prospective Studies | 7 | 2024 | 7604 | 0.100 |
Why?
| | Kidney Transplantation | 2 | 2003 | 708 | 0.100 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2004 | 25 | 0.100 |
Why?
| | Tissue Donors | 4 | 2024 | 425 | 0.100 |
Why?
| | Counseling | 1 | 2016 | 391 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2011 | 239 | 0.100 |
Why?
| | Cell Differentiation | 4 | 2024 | 1991 | 0.100 |
Why?
| | Species Specificity | 4 | 2017 | 585 | 0.100 |
Why?
| | Seals, Earless | 1 | 2012 | 5 | 0.100 |
Why?
| | Exome | 1 | 2014 | 231 | 0.100 |
Why?
| | Genetics, Medical | 3 | 2019 | 26 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2020 | 1043 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 406 | 0.100 |
Why?
| | Stress, Psychological | 2 | 2016 | 1100 | 0.100 |
Why?
| | Metagenomics | 1 | 2014 | 169 | 0.100 |
Why?
| | Anxiety Disorders | 1 | 2016 | 377 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2019 | 3715 | 0.100 |
Why?
| | Saliva | 1 | 2014 | 242 | 0.100 |
Why?
| | Hepatitis C | 1 | 2015 | 271 | 0.100 |
Why?
| | Graft Survival | 1 | 1995 | 535 | 0.090 |
Why?
| | CD56 Antigen | 2 | 2009 | 35 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1081 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2014 | 266 | 0.090 |
Why?
| | Environment | 1 | 2013 | 358 | 0.090 |
Why?
| | Self Efficacy | 1 | 2015 | 396 | 0.090 |
Why?
| | Genes, Overlapping | 1 | 2011 | 2 | 0.090 |
Why?
| | Interviews as Topic | 2 | 2024 | 786 | 0.090 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 3 | 2017 | 8 | 0.090 |
Why?
| | Interferon-gamma | 2 | 2017 | 789 | 0.090 |
Why?
| | Internet | 1 | 2015 | 655 | 0.090 |
Why?
| | Hybridization, Genetic | 1 | 2011 | 78 | 0.090 |
Why?
| | Graft Rejection | 1 | 1995 | 624 | 0.090 |
Why?
| | DNA Primers | 3 | 2018 | 515 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 617 | 0.090 |
Why?
| | Immunoglobulin G | 1 | 1995 | 893 | 0.080 |
Why?
| | Europe | 2 | 2021 | 414 | 0.080 |
Why?
| | North America | 2 | 2021 | 313 | 0.080 |
Why?
| | Cost-Benefit Analysis | 3 | 2025 | 591 | 0.080 |
Why?
| | Family | 1 | 2014 | 671 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1291 | 0.080 |
Why?
| | Mass Spectrometry | 1 | 2013 | 739 | 0.080 |
Why?
| | Gene Conversion | 1 | 2009 | 7 | 0.080 |
Why?
| | Gene Products, nef | 1 | 2009 | 12 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2024 | 10811 | 0.080 |
Why?
| | Receptors, IgG | 2 | 2014 | 75 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 480 | 0.080 |
Why?
| | Organ Transplantation | 1 | 2013 | 250 | 0.080 |
Why?
| | Hospitalization | 2 | 2023 | 2199 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2017 | 986 | 0.080 |
Why?
| | Algorithms | 3 | 2024 | 1704 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1809 | 0.070 |
Why?
| | Insulin | 1 | 2019 | 2409 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2009 | 105 | 0.070 |
Why?
| | Antigens, Bacterial | 1 | 2009 | 127 | 0.070 |
Why?
| | Africa | 3 | 2019 | 108 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2531 | 0.070 |
Why?
| | Nutritional Status | 2 | 2021 | 350 | 0.070 |
Why?
| | Homocysteine | 1 | 2008 | 156 | 0.070 |
Why?
| | Breast Neoplasms | 4 | 2002 | 2253 | 0.070 |
Why?
| | Databases, Factual | 1 | 2013 | 1357 | 0.070 |
Why?
| | Regression Analysis | 2 | 2021 | 1024 | 0.070 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2009 | 375 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.070 |
Why?
| | HIV Infections | 1 | 2022 | 2836 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1329 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2526 | 0.070 |
Why?
| | Palliative Care | 1 | 2014 | 758 | 0.070 |
Why?
| | Receptors, Fc | 1 | 2007 | 53 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 385 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4295 | 0.070 |
Why?
| | Genetic Counseling | 3 | 2002 | 77 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2025 | 951 | 0.060 |
Why?
| | Immunoglobulin A | 1 | 2007 | 211 | 0.060 |
Why?
| | Trinidad and Tobago | 2 | 2002 | 2 | 0.060 |
Why?
| | HLA-DR Antigens | 2 | 2006 | 228 | 0.060 |
Why?
| | Norway | 1 | 2025 | 43 | 0.060 |
Why?
| | Genetic Loci | 2 | 2019 | 288 | 0.060 |
Why?
| | Equivalence Trials as Topic | 1 | 2025 | 9 | 0.060 |
Why?
| | Ireland | 1 | 2025 | 30 | 0.060 |
Why?
| | Mice | 5 | 2025 | 17787 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2828 | 0.060 |
Why?
| | INDEL Mutation | 1 | 2025 | 16 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2008 | 379 | 0.060 |
Why?
| | Jurkat Cells | 2 | 2019 | 134 | 0.060 |
Why?
| | Kinetochores | 1 | 2025 | 53 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2017 | 4193 | 0.060 |
Why?
| | Patient Satisfaction | 3 | 2024 | 660 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2025 | 3015 | 0.060 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3412 | 0.060 |
Why?
| | Models, Statistical | 2 | 2019 | 669 | 0.060 |
Why?
| | Logistic Models | 2 | 2021 | 2074 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 160 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2025 | 5757 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 310 | 0.050 |
Why?
| | Histocompatibility | 1 | 2003 | 28 | 0.050 |
Why?
| | HeLa Cells | 2 | 2015 | 636 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2024 | 135 | 0.050 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2003 | 2 | 0.050 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2003 | 26 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2004 | 168 | 0.050 |
Why?
| | Granzymes | 1 | 2023 | 50 | 0.050 |
Why?
| | Cell Communication | 1 | 2005 | 315 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2007 | 450 | 0.050 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2022 | 6 | 0.050 |
Why?
| | Gene Library | 2 | 2014 | 118 | 0.050 |
Why?
| | Lymphocytes | 1 | 2005 | 397 | 0.050 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2022 | 28 | 0.050 |
Why?
| | Neoplasms | 1 | 2017 | 2671 | 0.050 |
Why?
| | Africa, Western | 1 | 2002 | 17 | 0.050 |
Why?
| | Chromosomes, Human | 1 | 2002 | 44 | 0.050 |
Why?
| | Pakistan | 1 | 2002 | 76 | 0.050 |
Why?
| | Bangladesh | 1 | 2002 | 56 | 0.050 |
Why?
| | Risk Assessment | 4 | 2019 | 3457 | 0.050 |
Why?
| | Pandemics | 2 | 2021 | 1639 | 0.050 |
Why?
| | HLA-DQ Antigens | 1 | 2002 | 181 | 0.050 |
Why?
| | Cloning, Molecular | 2 | 2014 | 534 | 0.050 |
Why?
| | India | 1 | 2002 | 195 | 0.050 |
Why?
| | Software Design | 1 | 2021 | 24 | 0.050 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 58 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 313 | 0.050 |
Why?
| | Databases, Nucleic Acid | 1 | 2021 | 34 | 0.050 |
Why?
| | Quantitative Trait, Heritable | 1 | 2002 | 125 | 0.040 |
Why?
| | Thailand | 1 | 2001 | 17 | 0.040 |
Why?
| | Cytokines | 2 | 2025 | 2085 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 879 | 0.040 |
Why?
| | Nutrition Assessment | 1 | 2021 | 92 | 0.040 |
Why?
| | Odds Ratio | 2 | 2017 | 1070 | 0.040 |
Why?
| | Geography | 1 | 2021 | 200 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 660 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2021 | 329 | 0.040 |
Why?
| | Cholesterol, HDL | 1 | 2021 | 203 | 0.040 |
Why?
| | Risk | 2 | 2019 | 912 | 0.040 |
Why?
| | Twins | 1 | 2001 | 243 | 0.040 |
Why?
| | Leadership | 1 | 2024 | 388 | 0.040 |
Why?
| | Prosthesis Design | 1 | 2022 | 327 | 0.040 |
Why?
| | Breathing Exercises | 1 | 2019 | 21 | 0.040 |
Why?
| | Respiratory Muscles | 1 | 2019 | 33 | 0.040 |
Why?
| | Genetic Markers | 1 | 2001 | 344 | 0.040 |
Why?
| | Newfoundland and Labrador | 1 | 2019 | 1 | 0.040 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2019 | 27 | 0.040 |
Why?
| | Electric Impedance | 1 | 2019 | 107 | 0.040 |
Why?
| | Deglutition | 1 | 2019 | 72 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2019 | 39 | 0.040 |
Why?
| | Patient Acuity | 1 | 2019 | 47 | 0.040 |
Why?
| | Autophagy | 1 | 2021 | 284 | 0.040 |
Why?
| | Interrupted Time Series Analysis | 1 | 2019 | 68 | 0.040 |
Why?
| | Hospital Units | 1 | 2019 | 29 | 0.040 |
Why?
| | Ketones | 1 | 2019 | 49 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2009 | 41 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 730 | 0.040 |
Why?
| | Celiac Disease | 1 | 2002 | 294 | 0.040 |
Why?
| | Nucleic Acid Denaturation | 1 | 2018 | 32 | 0.040 |
Why?
| | Hospitals, Community | 1 | 2019 | 52 | 0.040 |
Why?
| | Group Processes | 1 | 2019 | 64 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2019 | 87 | 0.040 |
Why?
| | Hepatitis B | 1 | 2019 | 70 | 0.040 |
Why?
| | Western Australia | 1 | 2018 | 8 | 0.040 |
Why?
| | Mutation | 3 | 2020 | 3958 | 0.040 |
Why?
| | Limit of Detection | 1 | 2018 | 85 | 0.040 |
Why?
| | Triglycerides | 1 | 2021 | 524 | 0.040 |
Why?
| | Cough | 1 | 2019 | 122 | 0.040 |
Why?
| | Posture | 1 | 2019 | 185 | 0.040 |
Why?
| | Research Design | 1 | 2025 | 1139 | 0.040 |
Why?
| | Disease Progression | 2 | 2017 | 2757 | 0.040 |
Why?
| | Chromosome Mapping | 2 | 2014 | 523 | 0.040 |
Why?
| | Narration | 1 | 2019 | 58 | 0.040 |
Why?
| | Particulate Matter | 1 | 2021 | 315 | 0.040 |
Why?
| | Body Height | 1 | 2019 | 199 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 916 | 0.040 |
Why?
| | Environmental Monitoring | 1 | 2021 | 370 | 0.040 |
Why?
| | Parenting | 1 | 2022 | 310 | 0.040 |
Why?
| | Biomarkers | 2 | 2021 | 4149 | 0.040 |
Why?
| | Ankle Brachial Index | 1 | 2018 | 37 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 160 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 1 | 2000 | 417 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 1060 | 0.040 |
Why?
| | Deglutition Disorders | 1 | 2019 | 143 | 0.040 |
Why?
| | Collagen Type III | 1 | 2017 | 16 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2017 | 18 | 0.030 |
Why?
| | Demography | 2 | 2013 | 291 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1167 | 0.030 |
Why?
| | Butyrophilins | 1 | 2017 | 6 | 0.030 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 7 | 0.030 |
Why?
| | Age Distribution | 1 | 2018 | 392 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 165 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 375 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 565 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2017 | 47 | 0.030 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2017 | 19 | 0.030 |
Why?
| | Health Equity | 1 | 2019 | 99 | 0.030 |
Why?
| | Elastin | 1 | 2017 | 78 | 0.030 |
Why?
| | Lymphocyte Count | 3 | 2002 | 148 | 0.030 |
Why?
| | Gorilla gorilla | 1 | 2017 | 23 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 252 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2017 | 83 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 614 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2018 | 404 | 0.030 |
Why?
| | Triage | 1 | 2019 | 222 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 978 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2017 | 132 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5131 | 0.030 |
Why?
| | Proteolysis | 1 | 2017 | 177 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2016 | 113 | 0.030 |
Why?
| | Cross Infection | 1 | 2019 | 256 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2017 | 172 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 847 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 399 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1943 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1430 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 234 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2019 | 318 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 73 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2015 | 17 | 0.030 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 98 | 0.030 |
Why?
| | Siberia | 1 | 2015 | 9 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 420 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1496 | 0.030 |
Why?
| | K562 Cells | 1 | 2015 | 89 | 0.030 |
Why?
| | Americas | 1 | 2015 | 28 | 0.030 |
Why?
| | Nursing Staff | 1 | 2016 | 50 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2016 | 165 | 0.030 |
Why?
| | Leukemia, Myeloid | 1 | 2015 | 45 | 0.030 |
Why?
| | History, Ancient | 1 | 2015 | 54 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2008 | 224 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2001 | 1091 | 0.030 |
Why?
| | Vascular Remodeling | 1 | 2017 | 193 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 657 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 740 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2016 | 237 | 0.030 |
Why?
| | Attitude | 1 | 2017 | 259 | 0.030 |
Why?
| | Patient Care Team | 1 | 2000 | 631 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 420 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 898 | 0.030 |
Why?
| | Fruit | 1 | 2015 | 140 | 0.030 |
Why?
| | Chromosomes, Mammalian | 1 | 2014 | 26 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 216 | 0.030 |
Why?
| | Social Support | 1 | 2019 | 618 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 327 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 222 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 351 | 0.030 |
Why?
| | Genetic Fitness | 1 | 2015 | 59 | 0.030 |
Why?
| | Inpatients | 1 | 2019 | 500 | 0.030 |
Why?
| | Vegetables | 1 | 2015 | 157 | 0.030 |
Why?
| | Smoking Prevention | 1 | 2015 | 184 | 0.030 |
Why?
| | Hypoglycemia | 1 | 2019 | 445 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2019 | 766 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 286 | 0.030 |
Why?
| | Models, Psychological | 1 | 2015 | 301 | 0.030 |
Why?
| | Caribbean Region | 1 | 2013 | 28 | 0.030 |
Why?
| | Inflammation | 1 | 2025 | 2837 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 286 | 0.030 |
Why?
| | United States | 2 | 2023 | 14841 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 87 | 0.030 |
Why?
| | Hepacivirus | 1 | 2015 | 261 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2015 | 377 | 0.030 |
Why?
| | Reproduction | 1 | 2015 | 204 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2015 | 184 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2015 | 275 | 0.030 |
Why?
| | Lung | 2 | 2019 | 4060 | 0.030 |
Why?
| | Asia | 2 | 2003 | 71 | 0.030 |
Why?
| | Cultural Competency | 1 | 2014 | 85 | 0.030 |
Why?
| | Ultrasonography | 1 | 2017 | 759 | 0.030 |
Why?
| | Ursidae | 1 | 2012 | 7 | 0.020 |
Why?
| | Smad Proteins | 1 | 2012 | 42 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 738 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1007 | 0.020 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2012 | 59 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 1975 | 308 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 364 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 200 | 0.020 |
Why?
| | Genome | 1 | 2014 | 300 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 984 | 0.020 |
Why?
| | Feces | 1 | 2015 | 484 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2016 | 956 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Quantitative Trait Loci | 1 | 2014 | 380 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 1992 | 99 | 0.020 |
Why?
| | Smoking Cessation | 1 | 2015 | 442 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3284 | 0.020 |
Why?
| | Models, Biological | 2 | 2016 | 1783 | 0.020 |
Why?
| | Dogs | 1 | 2012 | 413 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2013 | 353 | 0.020 |
Why?
| | Family Practice | 1 | 1975 | 464 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2011 | 56 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1040 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2011 | 48 | 0.020 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2012 | 131 | 0.020 |
Why?
| | Twins, Dizygotic | 2 | 2001 | 175 | 0.020 |
Why?
| | Uterus | 1 | 2011 | 215 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 366 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2012 | 320 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4030 | 0.020 |
Why?
| | Twins, Monozygotic | 2 | 2001 | 203 | 0.020 |
Why?
| | Culture | 1 | 2011 | 128 | 0.020 |
Why?
| | HLA-A11 Antigen | 1 | 2009 | 1 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1946 | 0.020 |
Why?
| | Antibody Affinity | 1 | 2009 | 60 | 0.020 |
Why?
| | Receptors, KIR2DL5 | 1 | 2009 | 1 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2475 | 0.020 |
Why?
| | Leucine | 1 | 2009 | 111 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 372 | 0.020 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2008 | 36 | 0.020 |
Why?
| | Pyridoxine | 1 | 2008 | 36 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 374 | 0.020 |
Why?
| | Aging | 1 | 2019 | 1864 | 0.020 |
Why?
| | Personality Inventory | 1 | 2008 | 139 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 265 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2009 | 476 | 0.020 |
Why?
| | Tryptophan | 1 | 2009 | 183 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 2008 | 128 | 0.020 |
Why?
| | Folic Acid | 1 | 2008 | 186 | 0.020 |
Why?
| | Hemodynamics | 1 | 2012 | 1113 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 706 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 860 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 294 | 0.020 |
Why?
| | Venezuela | 1 | 2006 | 8 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2007 | 148 | 0.020 |
Why?
| | Microbiota | 1 | 2014 | 762 | 0.020 |
Why?
| | Rabbits | 1 | 2007 | 794 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2005 | 22 | 0.010 |
Why?
| | Placenta | 1 | 2011 | 750 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2005 | 75 | 0.010 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 87 | 0.010 |
Why?
| | Microspheres | 1 | 2005 | 137 | 0.010 |
Why?
| | Cell Separation | 1 | 2005 | 318 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2005 | 318 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1250 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2003 | 51 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2002 | 16 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2009 | 1164 | 0.010 |
Why?
| | HLA-DQ beta-Chains | 1 | 2002 | 63 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 342 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1477 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 268 | 0.010 |
Why?
| | Genes, bcl-2 | 1 | 2002 | 21 | 0.010 |
Why?
| | Utah | 1 | 2002 | 69 | 0.010 |
Why?
| | Living Donors | 1 | 2003 | 295 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 530 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 15657 | 0.010 |
Why?
| | Genes, BRCA1 | 1 | 2000 | 40 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 2000 | 180 | 0.010 |
Why?
| | BRCA2 Protein | 1 | 2000 | 63 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 890 | 0.010 |
Why?
| | Ambulatory Care Facilities | 1 | 2000 | 232 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2001 | 1509 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2000 | 1316 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 434 | 0.010 |
Why?
| | Autoimmune Diseases | 1 | 2000 | 460 | 0.010 |
Why?
| | Hospital Departments | 1 | 1975 | 10 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2000 | 786 | 0.010 |
Why?
| | Receptors, Leukotriene B4 | 1 | 1992 | 7 | 0.010 |
Why?
| | SRS-A | 1 | 1992 | 31 | 0.010 |
Why?
| | Receptors, Leukotriene | 1 | 1992 | 14 | 0.010 |
Why?
| | Dicarboxylic Acids | 1 | 1992 | 9 | 0.010 |
Why?
| | Leukotriene E4 | 1 | 1992 | 27 | 0.010 |
Why?
| | Propionates | 1 | 1992 | 39 | 0.010 |
Why?
| | Transcription Factors | 1 | 2000 | 1719 | 0.010 |
Why?
| | Cysteine | 1 | 1992 | 204 | 0.010 |
Why?
| | Muscle Contraction | 1 | 1992 | 424 | 0.000 |
Why?
|
|
Norman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|